Skip to main content
Equibles
ALZN logo

ALZN · Alzamend Neuro, Inc.

Track ALZN — free

Use ALZN with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.70 +0.06 (+3.85%) At close · Sep 2
Rebalance outlook locked
Going-concern doubt — flagged Jul 22, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Our independent registered public accounting firm has issued a report on our financial statements for the year ended April 30, 2026, that contains an emphasis of a matter paragraph expressing substantial doubt about our ability to continue as a going concern due to insufficient capital for us to fund our operations.”
View the 10-K filed Jul 22, 2026
Market Cap
$8.15M
Shares
4.79M

ALZN metrics

49 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.70
Market cap
$8.15M

Price action

19 metrics
Price change (1W)
+2.3%
Price change (30D)
+22.1%
Price change (3M)
+43.6%
Price change (6M)
-12.9%
Price change (YTD)
-10.1%
Price change (1Y)
-32.9%
Trailing year
Price change (5Y)
—
52-week high
$2.62
52-week low
$0.86
Change from 52-week high
-37.5%
Change from 52-week low
+90.8%
Annualized volatility
76.6%
Beta
1.8
RSI (14D)
62.5
Price vs SMA 50
+19.6%
Price vs SMA 200
+1.7%
Avg volume (3M)
153,732
Relative volume
0.2
Average dollar volume
$196,025

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
4.79M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
10.5
reciprocal yield 9.6%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-114.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$8.77M
Net income (TTM)
−$8.77M
Trailing 12 months
Diluted EPS (TTM)
$-2.63
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$17.13

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
-108.6%
Shares change YoY
+521.7%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-1,196.4%
Return on assets
-421.9%
Debt / equity
—
Current ratio
—
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
-1,324.5
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$710,689
Latest balance sheet
Cash & equivalents
$710,689
Total assets
$2.08M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$8.07M
Capital expenditures (TTM)
—
R&D (TTM)
$3.63M
SG&A (TTM)
—
Stock compensation (TTM)
$707,527
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
12
13F filer change QoQ
-1
Institutional ownership
56.8%

Short interest

3 metrics
Short interest
3.7%
Latest settlement · 3.7 days to cover
Days to cover
3.7d
Short-squeeze score
64 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$3,116
Insider-sentiment score
48 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1677077 CUSIP 02262M605 13F (30d) 11 filings 10 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)